These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32112872)

  • 1. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
    Weir MR; Ashton V; Moore KT; Shrivastava S; Peterson ED; Ammann EM
    Am Heart J; 2020 May; 223():3-11. PubMed ID: 32112872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study.
    Fu EL; Desai RJ; Paik JM; Kim DH; Zhang Y; Mastrorilli JM; Cervone A; Lin KJ
    Am J Kidney Dis; 2024 Mar; 83(3):293-305.e1. PubMed ID: 37839687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
    Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL
    Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.
    Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
    Curr Med Res Opin; 2020 Jul; 36(7):1081-1088. PubMed ID: 32347755
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
    Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
    Coleman CI; Thompson S; Ashton V; Palladino M; Bunz TJ
    J Natl Med Assoc; 2020 Aug; 112(4):395-401. PubMed ID: 32493618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes.
    Hernandez AV; Bradley G; Khan M; Fratoni A; Gasparini A; Roman YM; Bunz TJ; Eriksson D; Meinecke AK; Coleman CI
    Eur Heart J Qual Care Clin Outcomes; 2020 Oct; 6(4):301-307. PubMed ID: 31432074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
    Milentijevic D; Lin JH; Connolly N; Chen YW; Kogan E; Shrivastava S; Sjoeland E; Alberts MJ
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105715. PubMed ID: 33743312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
    Coleman CI; Antz M; Bowrin K; Evers T; Simard EP; Bonnemeier H; Cappato R
    Curr Med Res Opin; 2016 Dec; 32(12):2047-2053. PubMed ID: 27633045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes.
    Baker WL; Beyer-Westendorf J; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
    Diabetes Obes Metab; 2019 Sep; 21(9):2107-2114. PubMed ID: 31099460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    J Diabetes Complications; 2021 Nov; 35(11):108029. PubMed ID: 34538715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.
    Weir MR; Berger JS; Ashton V; Laliberté F; Brown K; Lefebvre P; Schein J
    Curr Med Res Opin; 2017 Oct; 33(10):1891-1900. PubMed ID: 28590785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
    Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Peterson ED; Ashton V; Chen YW; Wu B; Spyropoulos AC
    Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
    Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
    Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.